Caribou Biosciences Shuts Down After Failing to Fund CAR-T Lymphoma Trial

Caribou Biosciences, a biotech company co-founded by Nobel Prize winner Jennifer Doudna, is shutting down after failing to secure funding for a late-stage clinical trial of its off-the-shelf CAR-T cell therapy designed to treat lymphoma. CAR-T therapy is an innovative immunotherapy approach that genetically engineers patients' immune cells to recognize and attack cancer cells. The company's closure represents a setback in developing more accessible CAR-T treatments, as off-the-shelf formulations could potentially benefit more patients compared to personalized approaches. This outcome highlights the significant financial challenges biotech companies face in advancing cancer treatments through clinical development stages.